KIAA1549 and neoplasm: For example, KIAA1549-BRAF has innate resistence to first-generation BRAFi vemurafenib as well as paradoxically triggered by PLX4720 treatment resulting in faster growth of tumor (90), while it shows a strong response to clinically available MEKi (e.g., trametinib) (206).